Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care View More Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Cases & Conversations™: Integrating Novel Approaches...
Fathi, 医学博士 † ‡ Þ Massachusetts General Hospital Cancer Center NCCN Guidelines 专家组公开组信息 Jordan Gauthier, 医学博士, 理科硕士 ‡ Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Nitin Jain, 医学博士† ‡ The University of Texas MD Anderson Cancer Center ...
4.Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome 机译:验证骨髓增生综合征患者患者较低风险的MD Anderson预后评分系统 作者:Komrokji Rami;Ramadan Hanadi;Al Ali Najla;Corrales-Yepez Maria;Zhang Ling;Padron Eric;Lancet Jeffrey;List Alan 期刊名称...
Median survival without therapy at MD Anderson in this group of pts is less than 60 days. To study the impact of therapy in patients not eligible for clinical trials, we conducted a phase II of the combination of 5-azacitidine and the histone deacetylase inhibitor vorinostat. The combination ...
The OncFive: Top Oncology Articles for the Week of 2/2 By Kristi Rosa February 8th 2025 MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML By Caroline Seymour February 8th 2025 Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML By Ashley Chan February 7th 2025 ...